Loading...
OTCM
BICX
Market cap6mUSD
Jun 13, Last price  
0.34USD
1D
11.11%
1Q
32.01%
IPO
-90.59%
Name

BioCorRx Inc

Chart & Performance

D1W1MN
OTCM:BICX chart
No data to show
P/E
—
P/S
753.94
EPS
—
Div Yield, %
—
Shrs. gr., 5y
24.32%
Rev. gr., 5y
-49.79%
Revenues
8k
-91.40%
000771,762868,161714,9621,170,922924,732701,772657,271376,656240,259122,62148,272213,84189,1607,665
Net income
-5m
L+35.55%
-5,021-13,197-23,086-408,967-885,807-3,838,522-3,127,780-4,665,990-5,903,982-29,705,669-6,511,891-7,708,270-4,014,989-5,803,167-4,369,413-3,766,913-5,106,124
CFO
-1m
L-40.85%
-1,046-7,750-15,510-129,290-927,758103,458167,66947,859-1,987,100-2,540,395-1,825,623-2,937,127-2,151,872-3,537,658-2,041,773-1,853,282-1,096,254

Profile

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
URL
https://www.biocorrx.com/
IPO date
Aug 31, 2010
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8
-91.40%
89
-58.31%
214
342.99%
Cost of revenue
1,483
927
1,475
Unusual Expense (Income)
NOPBT
(1,475)
(838)
(1,261)
NOPBT Margin
Operating Taxes
(106)
(7)
Tax Rate
NOPAT
(1,369)
(838)
(1,253)
Net income
(5,106)
35.55%
(3,767)
-13.79%
(4,369)
-24.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
213
915
1,250
BB yield
-5.37%
-14.06%
-17.81%
Debt
Debt current
2,576
1,851
1,423
Long-term debt
429
217
571
Deferred revenue
4
4
Other long-term liabilities
4,303
3,823
3,345
Net debt
2,918
2,003
1,925
Cash flow
Cash from operating activities
(1,096)
(1,853)
(2,042)
CAPEX
2
Cash from investing activities
Cash from financing activities
1,119
1,850
2,025
FCF
(119)
129
(484)
Balance
Cash
88
65
69
Long term investments
Excess cash
88
61
58
Stockholders' equity
(83,309)
(78,102)
(74,332)
Invested Capital
78,064
73,911
71,157
ROIC
ROCE
28.12%
19.99%
39.72%
EV
Common stock shares outstanding
10,464
8,344
7,198
Price
0.38
-51.28%
0.78
-20.00%
0.98
-77.48%
Market cap
3,976
-38.90%
6,508
-7.27%
7,018
-75.03%
EV
6,681
8,404
8,840
EBITDA
(1,380)
(638)
(1,119)
EV/EBITDA
Interest
1,528
887
1,087
Interest/NOPBT